Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of marginal zone lymphomas.

Catherine Thieblemont1, Bertrand Coiffier

  • 1Service d'hematologie clinique, Pavillon 1F, Centre Hospitalier Lyon-Sud, F-69495 Pierre-Benite Cedex, France.

Current Treatment Options in Oncology
|April 18, 2006
PubMed
Summary

Marginal zone lymphoma (MZL) has three subtypes with distinct clinical presentations and prognoses. This review details current treatment strategies for MALT, splenic, and nodal MZL.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.

Nature medicine·2022
Same author

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.

Blood·2022
Same author

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.

American journal of hematology·2022
Same author

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.

Blood advances·2022
Same author

The use of ICU resources in CAR-T cell recipients: a hospital-wide study.

Annals of intensive care·2022
Same author

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.

Blood advances·2022

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Marginal zone lymphoma (MZL) encompasses three distinct subtypes: extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma), splenic MZL, and nodal MZL.
  • All subtypes share a common cell of origin and are potentially linked to chronic antigenic stimulation.
  • Despite common origins, clinical presentations and prognoses vary significantly based on lymphoma location.

Purpose of the Study:

  • To review the current understanding of marginal zone lymphoma (MZL) subtypes.
  • To discuss the clinical presentations, prognostic factors, and treatment strategies for MALT, splenic, and nodal MZL.

Main Methods:

  • This is a review article.
  • Literature search on marginal zone lymphoma subtypes, clinical features, and treatment modalities.

Main Results:

  • MALT lymphoma and splenic MZL are typically indolent with good prognosis and long survival.
  • Nodal MZL is associated with shorter progression-free survival.
  • Prognostic factors for MZL are heterogeneous and optimal treatment strategies require further definition.

Conclusions:

  • MZL subtypes exhibit diverse clinical behaviors and prognoses.
  • Current treatment strategies for MZL subtypes are varied, and optimal approaches are still under investigation.
  • Further research is needed to define the best treatment protocols for each MZL subtype.

Related Experiment Videos